We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
101
Zai Lab
ZLAB
$2.29B
$3.71M 0.06%
+135,000
New +$3.56M
AZN icon
102
AstraZeneca
AZN
$256B
$3.48M 0.05%
25,800
-16,500
-39% -$2.14M
SIBN icon
103
SI-BONE Inc
SIBN
$763M
$2.63M 0.04%
+125,200
New +$2.32M
CVS icon
104
CVS Health
CVS
$137B
$2.49M 0.04%
31,503
-3,811
-11% -$271K
MCK icon
105
McKesson
MCK
$97.7B
$2.25M 0.03%
4,853
-572
-11% -$260K
BIIB icon
106
Biogen
BIIB
$29.9B
$2.2M 0.03%
8,485
-8,829
-51% -$2.17M
KRTX
107
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.93M 0.03%
6,100
-800
-12% -$156K
IQV icon
108
IQVIA
IQV
$34.2B
$1.91M 0.03%
8,260
-146,960
-95% -$30.2M
RXRX icon
109
Recursion Pharmaceuticals
RXRX
$1.55B
$1.72M 0.03%
174,557
+472
+0.3% +$3.37K
KOS icon
110
Kosmos Energy
KOS
$1.39B
$1.72M 0.03%
256,500
-27,500
-10% -$192K
LH icon
111
Labcorp
LH
$23B
$1.61M 0.02%
7,089
+101
+1% +$21.2K
CERT icon
112
Certara
CERT
$1.08B
$1.6M 0.02%
91,215
-391
-0.4% -$5.73K
CYTK icon
113
Cytokinetics
CYTK
$10.9B
$1.58M 0.02%
18,900
-18,200
-49% -$659K
RYTM icon
114
Rhythm Pharmaceuticals
RYTM
$7.26B
$1.51M 0.02%
32,869
-40,431
-55% -$1.28M
ALKS icon
115
Alkermes
ALKS
$8.69B
$1.45M 0.02%
52,112
-29,588
-36% -$769K
BBIO icon
116
BridgeBio Pharma
BBIO
$16B
$1.34M 0.02%
33,300
-45,400
-58% -$1.36M
SPY icon
117
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$1.24M 0.02%
2,600
– –
ZTS icon
118
Zoetis
ZTS
$32B
$1.14M 0.02%
5,790
-672
-10% -$119K
ABBV icon
119
AbbVie
ABBV
$448B
$1.04M 0.02%
6,727
+1,964
+41% +$286K
GDX icon
120
VanEck Gold Miners ETF
GDX
$21.7B
$1.02M 0.02%
33,000
– –
XENE icon
121
Xenon Pharmaceuticals
XENE
$6.52B
$1.01M 0.02%
22,000
-1,900
-8% -$67.1K
KRYS icon
122
Krystal Biotech
KRYS
$10.1B
$992K 0.02%
8,000
-4,500
-36% -$499K
PCVX icon
123
Vaxcyte
PCVX
$8.02B
$992K 0.02%
15,800
-14,700
-48% -$763K
INBX
124
DELISTED
Inhibrx, Inc. Common Stock
INBX
$935K 0.01%
24,600
-24,200
-50% -$519K
GOOG icon
125
Alphabet (Google) Class C
GOOG
$4.29T
$846K 0.01%
6,000
– –
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.